Which patients were included in this study?
Studies have a list of requirements for patients who can enrol (inclusion criteria) and
those who can’t (exclusion criteria). For this study, the main inclusion and exclusion
criteria are listed below.
Males and females were included in the study if they:
• Were at least 12 years old.
• Had been diagnosed with HES for at least six months before
starting the study treatment.
• Had a blood eosinophil level of at least 1000 cells/microlitre
before starting the study.
• Were on stable HES treatment for four weeks before starting the
study treatment.
• Had at least two HES flares in the year before starting the study.
Males and females were excluded from the study if they had:
• Life-threatening HES.
• A specific genetic change that could lead to increased eosinophil
levels.
• Abnormalities in other laboratory values.
• Received mepolizumab in the four months before starting the
study treatment.
• Any other disease(s) or had taken any medicine(s) before starting
the study, that the study doctor thought would affect the results
of the study.
Overall, 108 patients received at least one dose of the study medicine. The study
included 51 (47%) males and 57 (53%) females. The average age was 46 years. The
youngest patient was 12 years old and the oldest patient was 82 years old.